Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Operational Fixes At Cipla But All Eyes On Generic Advair

Executive Summary

Cipla is implementing certain operational fixes and tweaks in its European and emerging markets businesses as it emerges from a weak fourth quarter that saw profits fall sharply, but limited visibility around the firm's Advair generic in certain key markets appeared to fluster some investors.

Advertisement

Related Content

Christmas Cheer For Cipla’s Seretide Equivalent In The UK
Cipla Sees Changed Profile; Wraps Up Europe Revamp
India Q1 Results Preview: Exclusivity, Compliance Are Key Talking Points
Cipla Trimming Jobs Amid Europe Business Rejig
What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK
Mylan's Generic Advair FDA Filing Puts Added Squeeze On GSK
Cipla Injects Scale With $550m US Buy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065271

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel